New Report Proposes Five “Big Ideas” to Transform Vaccine R&D

05.12.21
The vaccine research and development (R&D) ecosystem has yielded life-saving products for decades by leveraging innovation, collaboration, and partnership; but the rapid development of COVID-19 vaccines illustrated that even more is possible when the right circumstances are in place to catalyze progress.
Read more

Vaccine Science and Policy Experts Call for Transformation of Vaccine R&D Enterprise

Submitted by Brittany Hackett on

In a new report, “Powering Vaccine R&D: Opportunities for Transformation,” the Sabin-Aspen Vaccine Science & Policy Group uses lessons learned from the rapid development of COVID-19 vaccines to explore opportunities to overhaul vaccine R&D practices to better prepare for the next pandemic, to make strides against diseases currently without vaccines, and to establish next-generation vaccines that offer meaningful improvements.

Clinical Vaccine Development

03.01.21

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

Read more

Dr. Regina Rabinovich Succeeds Dr. Axel Hoos as Sabin Vaccine Institute Board Chair, Drs. Norman Baylor and JoAnn Suzich Join the Board

Submitted by Greg Bodwell on

The Sabin Vaccine Institute (Sabin) is pleased to announce the Board of Trustees has unanimously elected Regina Rabinovich, MD, MPH, as board chair and elected two new trustees, Dr. Norman Baylor and Dr. JoAnn Suzich, to strengthen the organization’s leadership in global immunization and vaccine research and development.

Beyond Morbidity and Mortality, Understanding the Burden of Enteric Fever in South Asia: New Results from Phase II of the Surveillance for Enteric Fever in Asia Project (SEAP)

12.11.20

Originally posted on Take on Typhoid

Read more

Intro to Vaccine R&D – Pre-Clinical Studies

12.09.20

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

Read more

Pivoting in a Pandemic: Transforming Labs to Test for COVID-19 in Bangladesh

12.02.20

This blog post is part of Sabin’s Pivoting in a Pandemic series, which captures stories of extraordinary leaders who are adapting to advance research and public health in the midst of the COVID-19 pandemic.

Read more

Intro to Vaccine R&D – How Vaccines Are Made

10.09.20

This blog post is part of Sabin’s Vaccine IQ: Intro to Vaccine Research & Development series, in which experts from Sabin’s Vaccine R&D team give an introduction to how vaccines are made, explaining the stages of research, development and testing vaccine candidates must go th

Read more

Sabin's President of Global Immunization Dr. Bruce Gellin Testifies at House Briefing on Approval Processes for Safe, Effective COVID-19 Vaccine

Submitted by Samia Kemal on

Bruce Gellin, M.D., M.P.H., president of Global Immunization at the Sabin Vaccine Institute (Sabin) and former Deputy Assistant Secretary for Health and Director of the National Vaccine Program Office at the U.S. Department of Health and Human Services (HHS), testified on July, 14, 2020, at the House Subcommittee on Economic and Consumer Policy’s briefing entitled “Guardrails to Ensure a Safe and Effective COVID-19 Vaccine.”

BARDA Provides the Sabin Vaccine Institute with an Additional $20 Million for Further Development of Ebola Sudan and Marburg Vaccines

Submitted by Liz Powell on

WASHINGTON, D.C. and ROME, Italy, May 13, 2020 – The Sabin Vaccine Institute (Sabin) and its partner ReiThera Srl today announced that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response within the U.S. Department of Health and Human Services, has exercised the first two options, valued at $20 million, under the 2019 contract to advance the development of vaccines against Ebola Sudan and Marburg viruses through Phase 2 clinical trials.

Pages